- Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus®
- All studies in the phase 3 “EDITION” clinical trial program, including a study with type 1 patients, met their primary endpoint
- Toujeo dossier accepted by the EMA
Paris, France, 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia) at any time of day, including night-time events, compared with Lantus® (insulin glargine [rDNA origin] injection, 100 U/mL). The pooled analysis comprised data from three differing type 2 patient populations. In this analysis, more pronounced, significant reductions in low blood sugar rates at any time of day, including nighttime, were observed with Toujeo during the 8-week titration period when compared with Lantus.
“Toujeo has been recently accepted for review by EMA and this important milestone is another step forward in expanding our insulin portfolio,” said Pierre Chancel, Senior VP, Global Diabetes Division, Sanofi. “We continue to be encouraged by the positive Phase 3 results from EDITION, which demonstrated the potential of Toujeo to help meet unmet needs of people living with diabetes.”
Type 2 Diabetes
The pooled analysis was comprised of studies I, II and III from the EDITION program, a worldwide and extensive series of Phase 3 studies evaluating the efficacy and safety of Toujeo in broader and diverse populations of people with type 2 diabetes. Full EDITION I and II results have been previously reported.
Full results from the EDITION III trial showed that significantly fewer people with type 2 diabetes, new to insulin therapy, experienced low blood sugar events during the night over the study period (post-hoc analysis) when treated with Toujeo compared with Lantus. This effect was numerically more pronounced, although not significant, during the first 8-week titration phase.
All of studies from the phase 3 EDITION clinical program presented at the 74th Scientific Sessions of the American Diabetes Association, like previously reported studies, met their primary endpoint by demonstrating similar blood sugar control with Toujeo as compared with Lantus.
Geremia Bolli, Principal Investigator of the EDITION III study and Professor of Endocrinology, University of Perugia, Italy, commented: “Low blood sugar events, at any time of the day or night, should not be underestimated – particularly for those who are starting out with a new or alternate insulin therapy. As it is well known in clinical practice, many people go through a sensitive phase when starting insulin, and they tend to drop the treatment or not properly up-titrate when exposed to low blood sugar events. Reducing low blood sugar events in this particular phase is relevant in helping patients better manage diabetes.’’
EDITION I/II/III Meta-Analysis
In a diverse population of people with type 2 diabetes (n=2476), a post-hoc pooled analysis of EDITION I, II and III demonstrated the rate ratio (per participant-year) of night-time low blood sugar events was reduced by 31% (significant) for Toujeo compared with Lantus over the 6-month study period (rate ratio: 0.69 [95% CI: 0.57 to 0.84]; p=0.0002). In addition, the rate ratio was reduced (per participant-year) by 14% (significant) for low blood sugar events at any time of the day for Toujeo vs. Lantus (RR: 0.86 [95% CI: 0.77 to 0.97]; p=0.0116).
The EDITION I/II/III meta-analysis abstract is titled: New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-analysis of Phase 3a EDITION Clinical Trials in People with T2DM. (Ritzel et al. Poster presentation, June 15, 2014 12:00 − 14:00 pm PDT [ABS 90-LB]).
EDITION III Full Results
In people with type 2 diabetes who failed to control their blood sugar levels by treatments other than insulin, EDITION III (n=878) met its primary endpoint by showing similar blood sugar level control (reduction in HbA1C) from baseline between Toujeo and Lantus at 6 months [LS mean change -1.42 (0.05) and -1.46 (0.05) respectively; difference 0.04% (95% CI: -0.09 to 0.17)].
The percentage of participants with severe or confirmed (defined by plasma glucose ≤70 mg/dL) night-time low blood sugar events (nocturnal hypoglycemia) from week 9 to month 6 (pre-specified main secondary endpoint) was similar. Over the 6-month treatment period, the incidence of any night-time low blood sugar events (% of participants with ≥1 event) was lower with Toujeo vs. Lantus [RR: 0.76 (95% CI: 0.59 to 0.99)], particularly in the insulin titration phase, with 26% risk reduction in patients experiencing night-time low blood sugar events with Toujeo vs. Lantus [RR: 0.74 (95% CI: 0.48 to 1.13)] during the first 8 weeks of treatment.
In addition, there was a 25% risk reduction (event/ participant-year) of low blood sugar events at any time of day or night across the entire 6-month study period for Toujeo vs. Lantus [RR: 0.75 (95% CI: 0.57 to 0.99)].There were similar findings between groups for adverse events, including hypersensitivity reactions (6.9% vs. 5.7%, respectively) and injection site reactions (3.9% vs. 4.8%, respectively).
The EDITION III abstract is titled: New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Insulin Naïve People with T2DM (EDITION 3). (Bolli et al. Oral presentation, June 14, 2014 09:00 am PDT [ABS 68-OR]).
Toujeo Dosing Variation Study
Three-month sub-studies of EDITION I and II in type 2 diabetes patients showed varying the timing of Toujeo injections by ± 3 hours at least two times each week resulted in similar blood glucose reduction and similar percentage of patients experiencing low blood sugar events compared with a fixed daily injection schedule.
The Toujeo -treatment groups of the original studies were further randomized to either a fixed dosing time (the same time in the evening) or an adaptable dosing regimen, which allowed 24 ± 3 hours between each dose of Toujeo on at least 2 days each week. This sub-study showed that the HbA1C change (primary endpoint) was similar between regimens [EDITION I: difference 0.05% (95% CI: -0.19 to 0.30); EDITION II: difference 0.13% (95% CI: -0.15 to 0.42)]. Percentages of participants with ≥1 low blood sugar event at any time of the day, or night, were also similar (EDITION I: 66.0% vs. 57.1% and EDITION II: 41.9% vs. 36.4%, for fixed vs. adaptable dosing time, respectively).
The Toujeo dosing variation study abstract is titled: New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs Fixed Dosing Intervals in People with T2DM. (Riddle MC et al. Poster presentation, June 14, 2014 11:30 am –13:30 pm PDT [ABS 919-P])
Type 1 Diabetes: EDITION IV Results
EDITION IV full results showed that people with type 1 diabetes, randomized to Toujeo, experienced similar night-time and any-time of the day low blood sugar event rates with Toujeo compared with Lantus. In the insulin initiation phase, which was the first 8 weeks of the study, night-time low blood sugar event rates were significantly lower with Toujeo, compared with Lantus. Furthermore, EDITION IV results demonstrated similar glucose lowering and adverse event results for Toujeo regardless of whether it was injected in the morning or in the evening in type 1 patients. Variability in dosing was also investigated in two new subgroup studies in EDITION I and EDITION II. These studies demonstrated that glucose lowering and adverse events were similar for Toujeo vs Lantus when patients were able to vary their dosing schedule by up to ±3 hours.
In people with type 1 diabetes, EDITION IV (n=549) met its primary endpoint by showing Toujeo was non-inferior to Lantus for blood sugar control at 6 months [LS mean change in HbA1C -0.40 (0.05) and -0.44 (0.05) respectively; difference 0.04% (95% CI: -0.10 to 0.19)]. In this study, participants were randomized 1:1:1:1 to once-daily Toujeo or Lantus, morning or evening, while continuing meal-time insulin.
Event rates of confirmed or severe low blood sugar at any time of day or night across the entire 6-month study was similar for the two groups. The study indicated a 31% relative risk reduction (significant; event/patient-year) in night-time low blood sugar events in the first 8 weeks for Toujeo vs. Lantus (7.8% vs. 11.2%, [RR: 0.69 (95% CI: 0.53 to 0.91)]. There were similar findings between
groups for adverse events. Neither glycemic control nor low blood sugar events differed between morning and evening injection groups.
The EDITION IV abstract is titled: Glycemic Control and Hypoglycemia with New Insulin Glargine 300U/mL in People with T1DM (EDITION 4). (P.D. Home et al. Poster presentation, June 15, 2014 12:00 − 14:00 pm PDT [ABS 80-LB]).
Toujeo® is the intended trade name for insulin glargine [rDNA origin] injection, 300 U/mL; formerly abbreviated as “U300”. U300 is not currently approved or licensed anywhere in the world.
On May 27, 2014, the European Medicines Agency (EMA) accepted Sanofi’s marketing authorization dossier for insulin glargine (rDNA origin) injection 300 U/mL, for EU countries.
Sanofi has submitted the New Drug Application (NDA) for insulin glargine [rDNA origin] injection, 300 U/mL to the U.S. Food and Drug Administration (FDA). The formal acceptance of the submission is pending.
Conference Call on Diabetes for the financial community
Sanofi will host a Thematic Conference Call on Diabetes for the financial community in connection with the upcoming American Diabetes Association’s Scientific Sessions.
The call/webcast will take place on Monday, June 16, 2014 at:
6 pm Paris (CEST) │5 pm London (BST) │12 pm New York (EDT) │9 am San Francisco (PDT)
The conference call will include a presentation followed by a Q&A session. It will be accessible through audio webcast at www.sanofi.com and via the following telephone numbers:
CALL IN NUMBERS
France
+33 (0) 1 70 77 09 44
UK
+44 (0) 203 367 9453
USA
+1 866 907 59 28
AUDIO REPLAY
An audio replay of the call will be available through the numbers below. The replay will be available approximately 2 hours after the end of the call
REPLAY NUMBERS
France
+33 (0) 1 72 00 15 00
UK
+44 (0) 203 367 9460
USA
+1 877 64 230 18
REPLAY ACCESS CODE 287626#
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Contacts:
Media Relations
Jack Cox
Tel.: + (33) 1 53 77 45 02
jack.cox@sanofi.com
Investor Relations
Sébastien Martel
Tel.: + (33) 1 53 77 45 45
ir@sanofi.com
Global Diabetes Communications
Tilmann Kiessling
Mobile: +(49) 17 26 15 92 91
Tilmann.kiessling@sanofi.com
U.S. Diabetes Communications
Susan Brooks
Office: +1 (0) 908 981 6566
Mobile: +1 (0) 201 572 49 94
susan.brooks@sanofi.com
- Report of legal documents concluded by DIGI Communications N.V. in January 2019 or in other period but effective in January 2019
- Digi Communications N.V. announces Availability of Preliminary Financial Report for the year ended December 31, 2018 for Digi Communications N.V. Group
- Mono Solutions launches a new interface to drive the ultimate do-it-with-me (DIWM) experience
- Digi Communications NV Announces Investor Call on the Preliminary Financial Results for the year ended 31 December 2018
- Digi Communications NV: New date of the Conference Call for the 2018 Preliminary financial results; Update to the 2019 Company’s Financial Calendar
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 4 and 8 February 2019
- R.W. Chelsea Holdings Ltd Starts To Hold Fixed Income Investor Meetings In Vienna, Zurich, Geneva and London
- Digi Communications N.V. successfully increased and priced its Offering at €200,000,000 5.0% additional senior secured notes due 2023
- Digi Communications N.V. to offer additional €125,000,000 5.0% senior secured notes due 2023; new notes will be consolidated and treated as its existing €350,000,000; adjustment on interim unaudited consolidated financial statements for the nine-month period ending September 30, 2018
- World's largest superhero statue to be built in Central Europe
- The resignation of Mr. Bendei Ioan – VP and executive director of RCS&RDS S.A., DIGI COMMUNICATIONS N.V.’s subsidiary in Romania
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 28 January 2019 – 1 February 2019
- RCH Group to Showcase Integrated Selling Solutions at EuroCIS
- Mono and bfound partner to expand digital offerings for small businesses in the Middle East
- Digi Communications N.V. publishes the Independent Limited Assurance Report in accordance with Law 24/2017 (Article 82) and FSA Regulation no. 5/2018
- ERRATA of the reports dated 15 Jan 2019 and 15 Oct 2018 regarding the legal acts concluded by DIGI Communications N.V. in Dec 2018 and Sep 2018
- REVEALED: Experts reveal the best dates to book your summer holiday in Spain
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 21 – 25 January 2019
- Céline Dion visite son premier concept store de vêtements CELINUNUNU à Paris
- Anytime, anywhere tailored learning opportunities for welding professionals and apprentices alike
- i5invest открива офис в България
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 14 - 18 January 2019
- Mono helps Fonecta strengthen their digital presence offering for SMBs
- The Bucharest Tribunal’s decision regarding the investigation conducted by the Romanian National Anti-corruption Directorate with respect to RCS & RDS S.A., Integrasoft S.R.L. and certain of their directors
- Digi Communications N.V.: Exercise of stock options by a PDMR in accordance with the stock option plan approved by the Company for the Romanian employees of the Group in 2017
- Report of legal acts concluded by DIGI Communications N.V. in accordance with Romanian Law no. 24/2017 and FSA Regulation no. 5/2018 for December 2018
- Digi Communications N.V.: resolution of the Board of Directors to convert class 1,200,000 A shares into an equal number of class B shares for the purpose of the ongoing employees and directors stock option plans
- CELINUNUNU OUVRE SON PREMIER POP-UP À PARIS
- DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 07 – 11 January 2019
- Digi Communications NV: Announcement of the Conference Call for the 2018 Preliminary financial results. Update to the 2019 Company’s Financial Calendar
- A new Government Emergency Ordinance imposing additional corporate taxes with impact on the telecommunications sector in Romania
- DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 31 December 2018-04 January 2019
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 24-28 Dec 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 17-21 Dec 2018
- US Customer Data Platform authority David Raab to Host First CDP Workshop in Belgium
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 10-14 Dec 2018
- US-amerikanischer Customer-Data-Platform-Experte David M. Raab leitet ersten gemeinsamen CDP-Workshop mit b.telligent in München
- Arriva Designflows, la prima competizione di mobile design in Italia
- BWW 2018 – Best Wine Critics of World have been selected – Jancis Robinson MW is the Winner!
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 3-7 December 2018
- Farming by Satellite Prize is won by Teagasc from Ireland
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 26-30 Nov 2018
- Notification shares buy-back: Digi Communications N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 19-23 November 2018
- First Non-Melanocytic Skin Cancer Patients treated with Rhenium-SCT® in South Africa
- Notification shares buy-back: Digi Communications N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 12-16 November 2018
- Base Element and Cognigy Announce Strategic Partnership
- Digi Communications N.V. announces the Hungarian Competition Council’s decision to formally withdraw and reassess the Invitel merger decision on certain limited aspects
- Amerikaanse Customer Data Platform authoriteit David M. Raab leidt eerste CDP Workshop in Nederland
- Digi Communications NV announces the release of the Q3 2018 Financial Results
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 5-9 November 2018
- Cobots and RPA Gain Centerstage in Automotive Robotics Space; Labor Issues Prevail as a Key Challenge
- Digi Communications NV announces Investor Call on the Financial Results for Q3 2018
- Food Waste Recycling Machine Sales to Reach 10,890 units in 2018 on the Back of Growing Investments in Sustainable Solutions
- SMEs Accounted for Nearly 60% Share of SAP Cloud Platform Services Market in 2017, Finds New Fact.MR Study
- China’s Dominance of Pneumatic Rollers Production and Demand Continues, Finds Fact.MR Study
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 29 October-2 November 2018
- ILC Dover to Open New Production Facility in Blarney, Ireland for Added Capabilities, Capacity and Jobs
- OEMs Hold 90% Share of Automotive Switches Sales Channel, Finds Fact.MR
- US$ 3 Billion RF Power Amplifiers Market Driven by Growing Cellular Applications, Finds Fact.MR Study
- Kidney Stone Management Device Sales to Surpass 340,000 Units in 2018 with Lithotripsy Devices Leading the Rally, Finds Fact.MR
- Fact.MR Study Finds Contractor Preference Shifting from Skid Steers to Compact Track Loaders in Lucrative Markets
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 22-26 October 2018
- DB CyberTech Launches into the European Market
- Hungarian coding bootcamp opens in Prague in order to train career changers looking to enter the IT industry
- Gasoline Vehicles Accounted for 8 in 10 Automotive Fuel Injector Sales in 2018, finds Fact.MR Study
- Fact.MR Study Finds Global Demand for Crawler Cranes to Reach 3,648 Units in 2018, Greater China Leads with 30% Share
- Surplus Supply Reflects Growing Avidity in the Europe Cocoa Market – Fact.MR Study
- Fact.MR Study Shows Declining Demand for Tilapia in US Offset by Encouraging Gains in Domestic Markets
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 15-19 October 2018
- Europe Home Diagnostics Market Driven by Burgeoning Glucose Monitoring Device Sales, Consumer Demand for Non-Invasive Kits Largely Unmet – Fact.MR Study
- Europe Bicycle Parking Racks Market Driven by Consumer Focus on Sustainability and Carbon Consciousness
- Halloumi Cheese Popularity Soars in Europe as UK Maintains its Lead as the Largest Market – Fact.MR Study
- Vehicle Interior Air Quality (VIAQ) Takes Centerstage in US$ 6.5 Million Europe Automotive Headliners Market
- Report of legal acts concluded by DIGI Communications N.V. in accordance with Romanian Law no. 24/2017 and FSA Regulation no. 5/2018 for September 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 8-12 Oct 2018
- Europe Emulsifier and Co-Emulsifier Market Witnessing a Shift Towards Bio-based Variants – Fact.MR Study
- Fact.MR Study on IBM Watson Services Market Lists Business Agility and Customer Service Transformation as Key Motivations to Adoption
- Europe Non-Dairy Toppings Market Riding on the Coattails of Growing Vegan Revolution, Finds a New Fact.MR Study
- Blockchain Cyber-security Firm Privus Raises $635k in Late Stage Seed Funding
- ‘Sustainability’, ‘Functionality’ and ‘Cost-Effectiveness’ Among Key Expectations of European Consumers from Automotive Tow Bars Industry
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 1-5 Oct 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 24-28 Sept 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 17-21 Sept 2018
- New Study Reconfirms Effectiveness and Safety of Fotona Dynamis Laser Treatment for Minimally-Invasive Urinary Incontinence
- New study reveals that hate speech is becoming the ‘new normal’ on social media
- The launch of fixed broadband and fixed telephony services by Digi Communication N.V.’s subsidiary in Spain
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 10-14 Sept 2018
- coMakeIT appoints Durga Prakash Kone as Head of Global Sales
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 3-7 Sept 2018
- 80% Satisfaction Rate in Europe for Customer Data Platform Early Adopters
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 27-31 Aug 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 20-24 Aug 2018
- DB CyberTech Launches GDPR Continuous Monitoring Solution with the First to Market Advanced Data Classification
- DATA4 Brings Pioneering Payment Systems to Kiosk Summit 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 13-17 Aug 2018
- Digi Communications NV announces the release of the Q2 2018 Financial Results
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 6-10 August 2018
- Plus Ultra strongly denies the fraud allegations bought against them in the Spanish class action lawsuit
- Digi Communications NV announces Investor Call on the Financial Results for H1 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 30 July-3 August 2018
- Europe’s largest battery and H/EV event moves to manufacturing hub for e-mobility
- Mono Solutions announce a new partnership with PA DIGITAL, the leading provider of digital services for small businesses in Spain
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 23-27 July 2018
- Digi Communications N.V. publishes report of legal acts concluded by the company in accordance with Romanian Law, FSA Regulation as well as the Independent Limited Assurance Report
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 16-20 July 2018
- RCH Europe Brings New Innovative Selling Solutions to FAFGA 2018
- Lanzamiento de un nuevo sitio web de comparación financiera
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 9-13 July 2018
- European Customer Data Platform Vendors Lead Industry in New Direction
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol, 2-6 July 2018
- iBwave Design Helps MTS Deliver Superior Fan Experience During the 2018 Soccer Games in Russia
- Get Ahead Of Your Business Competition with Customized Advertising Campaigns by Manesta Programmatic Agency
- Digi Communications N.V. announces the publishing of ANCOM approval for RCS & RDS S.A. to continue to apply a surcharge for certain roaming services provided in the EEA for a renewed period of 12 months
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 25-29 June 2018
- Euro Staff Solution: First 2 Employees are on Us
- Press conference: Illegal sales of Schengen and Medical Visa Scandal involving Maltese PM’s Office
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol between 18-22 June 2018
- Notification shares buy-back: DIGI COMMUNICATIONS N.V. reports to the regulated market the transactions which occurred under the DIGI symbol (June 11-15, 2018)
- Settlement of litigations between RCS & RDS S.A. and Antena Group entities
- Dr. Christina Marrongelli to lead World Congress on Pharmacology & Chemistry of Natural Compounds
- Report of legal acts concluded by DIGI Communications N.V. in accordance with Romanian Law no. 24/2017 and Rule no. 1/2006 of CNVM – May 2018
- 40 miljoen liter verdwijnt onnodig in het europese millieu | Stem op Cleanprotec | Dave Bebelaar award 2018
- Mit der Eröffnung eines neuen Büros in Spanien stärkt IN-GRY seine Präsenz in Europa
- Con la inauguración de una nueva sede en España, INRGY reforzará su presencia en Europa
- With the opening of a new office in Spain, IN-RGY strengthens its business presence in Europe
- Avec l’ouverture d’un nouveau bureau en Espagne, IN-RGY renforce sa présence commerciale en Europe
- Revealed: Top Tips for Sunseekers on a Shoestring in Spain
- Qoobo, a Pillow That Wags Its Tail to Your Touch, Is Coming to CEBIT
- Digi Communications NV: The initiation by the Company of the share buy-back program as authorized by the Company’s GSM from 2 May 2018
- NIKITA ONLINE veröffentlicht ein neues Spiel: «Panic Room 2: Versteckspiel»!
- NIKITA ONLINE lance un nouveau jeu «Panic Room 2: Jeu de cache-cache»!
- NIKITA ONLINE launches a new game, «Panic Room 2: Hide and Seek»!
- Nagarro sets up technical center in Malta to focus on growing iGaming clientele
- Digi Communications NV: The closing of the acquisition by the Company’s Hungarian subsidiary, DIGI Távközlési és Szolgáltató Kft., of the Hungarian telecommunications operator Invitel Távközlési Zrt.
- Digi Communications NV Stock option plan meant for the employees and officers of Digi Spain S.L.U. and conditional stock options granted to certain Romanian directors and employees
- Leading European Crowdfunding Firm FundedByMe Kicks-Off Property Portal MIPARO’s Campaign May 21
- Digi Communications NV Announces that Conditional stock options were granted to several Directors of the Company based on the general shareholders’ meeting approval from 2 May 2018
- Digi Communications NV Announces the Exercise of stock options in accordance with the stock option plan approved at the level of the Company in 2017 for its Executive Directors
- Vor Beyoncés Blockbuster-Tournee durch Deutschland im Juli 2018 erscheint die lang erwartete Beyoncé und Destiny’s Child Dokumentation, die bei Amazon Direct in Deutschland erhältlich is
- Launch of new research journals European Journal of Sciences (EJS)® & European Journal of Social Sciences (EJSS)®
- Silver is Gold: The first European Silver Economy Awards have announced its winners
- Icelandair en het nationaal voetbalelftal creëren samen de Team Iceland Stopover: een reeks van 90 minuten durende, op voetbal geïnspireerde ervaringen
- Icelandair en collaboration avec l’équipe nationale de football créent la Team Iceland Stopover – une série d’expériences de 90 minutes inspirées du football
- Icelandair und die Fußballnationalmannschaft gestalten gemeinsam Team Iceland Stopover – eine Reihe von 90-minütigen, vom Fußball inspirierten Erlebnissen
- Icelandair and national football team co-create Team Iceland Stopover – a series of 90-minute football-inspired experiences
- Anti-rating: No leap of faith here: 15 countries with restrictions on cryptocurrency transactions
- ZOOM International Introduces GDPR Compliance in 6.3 Release
- Finer.es comienza su actividad
- Animal rescue hero loses his heroic battle with cancer
- International Association of Trampoline Parks (IATP) Jumping to New Heights in Europe – 2nd Annual EU Conference & Trade Show
- CONDA ICO: Whitelisting phase started as of April 1st
- International Day of Riding Announced
- April 10th, Conference in the European Parliament, Brussels, themed: A FUTURE FOR DEMOCRACY IN SYRIA
- Mono Solutions and Orange partner to expand digital services for SMBs in France
- Alliance Life Sciences is a Sponsor at World Pharma Pricing and Market Access Congress 2018, Showcasing Data and Technology Solutions
- Harald Xperience first in Finland to take augmented reality (AR) to restaurants
- 2018 ‘Farming by Satellite’ Prize seeks entries from across Europe
- BookingPal étend ses activités en France à mesure que les opérations européennes grandissent
- Schuster Manfred Hubert agrees with future oil predictions
- World Life Experience is headed to Ljubljana
- Whirlpools World Spain eröffnet in Teulada größten Whirlpool-Showroom in ganz Spanien
- Whirlpools World Spain opens biggest whirlpool bath showroom in the whole country
- RCH Group to Showcase Innovative Selling Solutions at EuroCIS
- MeetingPackage.com Präsentiert einzigartiges Reservierungsportal für Meetings & Events
- MeetingPackage.com Lance son Moteur de Réservation Exclusif pour Réunions & Événements
- MeetingPackage.com Introduces Unique Booking Engine for Meetings & Events
- ANECON becomes Nagarro
- UK Education Consultancy Services Ltd announced that the premiere issue of Scientific European® (a popular science magazine) is released on 19 January 2018
- RCH Europe to Present Smart Solutions for POS at INTERGASTRA 2018
- Raport: Jak zaoszczędzić na hiszpańskich wakacjach nad morzem
- Onthuld: zo vind je de beste deals voor je zomervakantie naar Spanje
- Finden Sie diesen Sommer die besten Spanien Angebote in der Zwischensaison
- Revealed: How to get the best value savings on your Spanish summer holiday
- Point of Sale Systems: RCH Group Expands European Operations
- Adomik a obtenu la 14e place au classement 2017 TECHNOLOGY FAST 500 pour la zone EMEA et la 3e place au classement Deloitte 2017 TECHNOLOGY FAST 50 pour la France
- Adomik auf Rang 14 der 2017 TECHNOLOGY FAST 500 EMEA und auf Platz 3 der Deloitte 2017 TECHNOLOGY FAST 50 für Frankreich
- Adomik Awarded #14 Ranking in 2017 TECHNOLOGY FAST 500, EMEA; #3 ranking in Deloitte 2017 TECHNOLOGY FAST 50 for France
- MeetingPackage.com Launches its Exclusive Affiliate Partner Program
- P2P Investment Loan Platform Enters Blockchain Sector with ICO Launch
- International Symposium on the Accessibility to High-Value Medicine, December 5-6, 2017, London
- Axiomatics Releases New Version of SmartGuard™ for Big Data
- No Time To Waste! Conference Takes a Practical Approach to Tackling Waste Crime
- HET DIGITALE EINDEJAARSVUURWERK VAN ONELIFE!
- LE FEU D’ARTIFICE DIGITAL DE FIN D’ANNEE DE ONELIFE !
- ONELIFE’S YEAR-END DIGITAL FIREWORKS!
- Alliance News riceve un investimento strategico da parte di PA Group e dpa per sostenere l’espansione nell’area EMEA
- #SUCCESVOL #VERHUIZEN: VERHUIZEN NAAR HET BUITENLAND
- #REUSSIR SON #EXPATRIATION: LE PARCOURS DE L’EXPATRIATION
- #SUCCESS IN #RELOCATION: THE RELOCATION JOURNEY
- 99X Technology hosts its first international breakfast seminar on digitalization in Oslo
- Spain-Holiday.com City Break Cost Index Autumn Winter 2017
- Continuing Growth Triggers Expansion and New Office in Spain for MeetingPackage.com
- 99X Technology drives digital disruption at Webdagene 2017 Oslo
- В Киеве состоится SphereCon 2017 – конференция, объединяющая Ruby on Rails, Go, разработчиков программного обеспечения и дизайнеров
- TechTrans Announces Partnership with Tidel (external link)
- Axiomatics Data-Centric Dynamic Authorization Product Suite Recommended in New KuppingerCole Analyst Report
- Throne of Lies, the highly anticipated online game of Deceit, launches on Steam
- SecBI and Innovery Announce Partnership to Promote SecBI’s “Autonomous Investigation” Cybersecurity Solution to the Italian and Spanish Markets
- "Heillandi Peking" Ljósmyndasýning um ferðalög haldin í Reykjavík
- Grammy Winner Coolio & Wrestling Legend Virgil on an Adult Star’s Presidential Ticket – Press Conference
- Invacare introduce their first touch screen remote
- Invacare International take powerchairs to a new level
- Industrial Laser Peening Research at ZAL Techcenter
- Blind Children Find New Hope Through Music in Wuhan, China
- Editor's pick archive....